利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

225 条记录 (耗时 0.034 秒)

    Intranasal vasopressin treatment of social deficits in autism
    5.
    发明授权
    Intranasal vasopressin treatment of social deficits in autism 有权

    公开(公告)号：US11951149B2

    公开(公告)日：2024-04-09

    申请号：US17252186

    申请日：2019-07-10

    申请人： The Board of Trustees of the Leland Stanford Junior University

    发明人： Karen J. Parker ,  Dean S. Carson ,  Antonio Y. Hardan

    IPC分类号： A61K38/095 ,  A61K9/00 ,  A61K38/09 ,  G01N33/74

    CPC分类号： A61K38/095 ,  A61K9/0043 ,  G01N33/74 ,  G01N2333/575

    摘要： Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.

    COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR
    7.
    发明公开
    COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR 审中-公开

    公开(公告)号：US20240024294A1

    公开(公告)日：2024-01-25

    申请号：US18037007

    申请日：2021-11-16

    申请人： XOMA (US) LLC

    发明人： Jean-Pierre GOTTELAND

    IPC分类号： A61K31/426 ,  A61K38/095 ,  A61P15/06

    CPC分类号： A61K31/426 ,  A61K38/095 ,  A61P15/06

    摘要： The disclosure provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered atosiban in combination with a prostaglandin F2α (PGF2α) antagonist. Exemplary PGF2α receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride). The compositions and methods described herein provide various clinical benefits. Delivery at an early gestational age is a leading cause of perinatal mortality. By delaying labor in pregnant human patients at an early gestational age, the compositions and methods of the disclosure provide unborn infants with additional time to develop vital organs and tissue systems, thereby significantly improving the likelihood of survival following delivery. The compositions and methods described herein may be used to delay the onset of delivery by one or more hours, days, or weeks, for example, so as to enable pregnant subjects to reach a gestational age at which parturition is substantially safer.